Evaluating Debio 1347 in patients with FGFR fusion-positive advanced solid tumors from the FUZE multicenter, open-label, phase II basket trial Journal Article
| Authors: | Grivas, P.; Garralda, E.; Meric-Bernstam, F.; Mellinghoff, I. K.; Goyal, L.; Harding, J. J.; Dees, E. C.; Bahleda, R.; Azad, N. S.; Karippot, A.; Kurzrock, R.; Tabernero, J.; Kononen, J.; Ng, M. C. H.; Mehta, R.; Uboha, N. V.; Bigot, F.; Boni, V.; Bowyer, S. E.; Breder, V.; Cervantes, A.; Chan, N.; Cleary, J. M.; Dhawan, M.; Eefsen, R. L.; Ewing, J.; Graham, D. M.; Guren, T. K.; Won Kim, J.; Koynov, K.; Oh, D. Y.; Redman, R.; Yen, C. J.; Spetzler, D.; Roubaudi-Fraschini, M. C.; Nicolas-Metral, V.; Ait-Sarkouh, R.; Zanna, C.; Ennaji, A.; Pokorska-Bocci, A.; Flaherty, K. T. |
| Article Title: | Evaluating Debio 1347 in patients with FGFR fusion-positive advanced solid tumors from the FUZE multicenter, open-label, phase II basket trial |
| Abstract: | PURPOSE: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1-3, in patients with solid tumors harboring a functional FGFR1-3 fusion. PATIENTS AND METHODS: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. RESULTS: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. CONCLUSIONS: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549. ©2024 American Association for Cancer Research. |
| Keywords: | adult; treatment outcome; aged; aged, 80 and over; middle aged; genetics; clinical trial; neoplasm; neoplasms; phase 2 clinical trial; protein kinase inhibitor; pathology; fibroblast growth factor receptor 3; protein kinase inhibitors; multicenter study; oncogene proteins, fusion; drug therapy; receptor, fibroblast growth factor, type 1; fibroblast growth factor receptor 1; receptor, fibroblast growth factor, type 3; fgfr1 protein, human; very elderly; humans; human; male; female; fgfr3 protein, human; oncogene fusion protein |
| Journal Title: | Clinical Cancer Research |
| Volume: | 30 |
| Issue: | 20 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2024-01-01 |
| Start Page: | 4572 |
| End Page: | 4583 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-24-0012 |
| PUBMED: | 38771739 |
| PROVIDER: | scopus |
| PMCID: | PMC11707795 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
269Mellinghoff -
250Harding
Related MSK Work